A retrospective cohort study finds increased healthcare costs in Medicare beneficiaries with metabolic dysfunction-associated steatohepatitis, indicating significant economic implications.
Among Medicare fee-for-service beneficiaries aged 66 years and older, MASH was associated with significantly greater HCRU and costs, even after adjustment for cardiometabolic and other comorbidities. The higher HCRU and costs are likely driven by the management of liver disease, which may include cirrhosis and hepatic decompensation.
No takes yet. Share an insight, caveat, or question.
Albarmawi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: